Icelanders, whose unusually low genetic variability makes them ideal for
studies on the origin of diseases, have agreed to reveal the secrets of their
genes to pharmaceuticals company Hoffmann-La Roche. The deal, worth $200
million, gives the company and its partner—deCode Genetics of
Reykjavik—exclusive rights to develop drugs from the genetic data of
Iceland’s population. In return, Icelanders will receive any resulting medicines
free.
More from ¿ìè¶ÌÊÓƵ
Explore the latest news, articles and features
Mathematics
Aim high but don't shoot for the moon, mathematicians advise
¿ìè¶ÌÊÓƵ
Technology
Horror video game gets its creepiness from a quantum computer
¿ìè¶ÌÊÓƵ
Mind
We're becoming more individualistic and it's affecting our love lives
¿ìè¶ÌÊÓƵ
Life
Mirror life: ¿ìè¶ÌÊÓƵs clash over threat of lab-engineered bacteria
¿ìè¶ÌÊÓƵ
Popular articles
Trending ¿ìè¶ÌÊÓƵ articles
1
Pancreatic cancer halted by virus injection in three patients
2
Glaciers in the 'roof of the world' have suddenly started melting
3
Does gravity create reality? A shocking path to a theory of everything
4
The ‘doomsday’ glacier’s giant ice shelf is about to break away
5
How a radical new view of life could reveal its origin – and aliens
6
Aim high but don't shoot for the moon, mathematicians advise
7
Embryos made without sperm or eggs reveal why many pregnancies fail
8
A miniature magnet rivals behemoths in strength for the first time
9
Solar farm on the ocean outperforms land-based solar in Taiwan
10
Mirror life: ¿ìè¶ÌÊÓƵs clash over threat of lab-engineered bacteria
